Year: 2023
Type: editorial
Abstract: The anti-Clever-1 MAb bexmarilimab (Faron Pharma) combined with chemotherapy induced >50% objective response rate in 15 patients with myelodysplastic syndromes and relapsed or refractory acute myel...
Authors: Ronald Ellis, Adam Weiss
Institution: Taylor and Francis (United Kingdom)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,175
OpenAlex ID: W4385620094